SRRK vs. SMMT, GMAB, VTRS, ITCI, MRNA, RDY, CTLT, SRPT, PCVX, and QGEN
Should you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Scholar Rock vs.
Summit Therapeutics (NASDAQ:SMMT) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Summit Therapeutics has a beta of -0.87, suggesting that its stock price is 187% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.
Scholar Rock has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics received 137 more outperform votes than Scholar Rock when rated by MarketBeat users. However, 65.87% of users gave Scholar Rock an outperform vote while only 58.38% of users gave Summit Therapeutics an outperform vote.
In the previous week, Scholar Rock had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 14 mentions for Scholar Rock and 10 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.65 beat Scholar Rock's score of 0.31 indicating that Summit Therapeutics is being referred to more favorably in the media.
Summit Therapeutics' return on equity of -85.42% beat Scholar Rock's return on equity.
4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 19.2% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summit Therapeutics presently has a consensus price target of $33.57, indicating a potential upside of 43.04%. Scholar Rock has a consensus price target of $40.43, indicating a potential downside of 9.87%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than Scholar Rock.
Summary
Scholar Rock beats Summit Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Scholar Rock News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scholar Rock Competitors List
Related Companies and Tools
This page (NASDAQ:SRRK) was last updated on 1/22/2025 by MarketBeat.com Staff
